Division of Rheumatology, Cedars-Sinai Medical Center, 8737 Beverly Blvd, Suite 302, West Hollywood, CA 90048, USA.
BMC Med. 2010 Nov 29;8:77. doi: 10.1186/1741-7015-8-77.
Systemic lupus erythematosus (SLE) is an autoimmune disorder that afflicts 500,000 people in the United States. There has not been a new SLE drug approved in the United States since 1958. However, a guidance document issued by the Food and Drug Administration in 2005 provided a roadmap for investigators which spawned numerous ongoing clinical trials. Among these, Belimumab, a monoclonal antibody to soluble B lymphocyte stimulator, met its primary endpoints in two large trials and will probably obtain FDA approval soon. Other promising agents targeting a variety of mechanisms of action are currently in development. This minireview highlights the latest therapies under investigation in SLE and gives an overview of the pathways that are specifically being targeted.
系统性红斑狼疮（SLE）是一种自身免疫性疾病，影响美国 50 万人。自 1958 年以来，美国尚未批准新的 SLE 药物。然而，2005 年食品和药物管理局发布的一份指导文件为研究人员提供了路线图，催生了许多正在进行的临床试验。其中，针对可溶性 B 淋巴细胞刺激物的单克隆抗体 Belimumab 在两项大型试验中达到了主要终点，可能很快就会获得 FDA 批准。其他针对各种作用机制的有前途的药物目前正在开发中。这篇迷你评论强调了 SLE 正在研究的最新疗法，并概述了正在针对的具体途径。
